Quebec City, January 24 th, 2018 – OPTEL GROUP, a leading global provider of traceability systems for the pharmaceutical, medical device, and healthcare industries, announced today that it has signed an agreement to pilot OPTEL’s Certa decommissioning solution at Oxford University Hospitals (OUH) to enable the world-renowned institution to comply with the European Union’s Falsified Medicines Directive (FMD).
This legislation states that, by February 9, 2019, European hospitals and retail pharmacies will be required to verify and decommission all prescription medications using their unique identifier before distributing them to patients.
This pilot project is extremely important for the healthcare industry because it will help define how hospital management teams can use this requirement to improve patient safety. In addition, it will be a concrete example of how this legislative change really affects hospital pharmacy operations and how these changes can improve operational efficiency roadmaps. “This is a massive opportunity to streamline processes and attain our ultimate goal of closed-loop medication management. It’s a key step in ensuring that we meet the WHO’s Third Global Patient Safety Challenge: Medication Without Harm and that patients are given the safest possible care,” declares Mr. Bhulesh Vadher, Clinical Director of Pharmacy & Medicines Management at Oxford University Hospitals NHS Foundation Trust.
Bernard Naughton, a clinical pharmacist and researcher of falsified and counterfeit drugs, agrees with this perspective adding that: “There are a number of different actions that need to be aligned to meet the February 2019 FMD deadline; however, the solutions and processes implemented for FMD compliance will also present great benefits both in terms of workflow operations and patient safety.”
The project builds upon the evidence recently published by Naughton et al. in the BMJ OPEN journal and is significant in that it can act as a case study to help identify, implement and validate the most effective way to decommission the high volume of medications that go in and out of hospital pharmacies on an annual basis in a safe and simple manner. “Legislations like these represent a turning point in the healthcare industry, and this project can help evaluate user adoption and determine best practices for compliance in real-world scenarios,” mentions Korina Fischer, Vice-President, Healthcare at OPTEL GROUP. “We are extremely pleased and honored that Oxford University Hospitals, one of the best research hospitals in the world, chose to collaborate with OPTEL, and we look forward to working with them on this,” concludes Ms. Fischer.
For more information on OPTEL’s new offering, visit www.optelhealthcare.com.
About OPTEL GROUP
Now a Certified B Corporation, OPTEL is a leading multinational provider of traceability systems, and its mission is to use its innovative technologies to create a better world. The company’s renowned solutions ensure the quality of consumer health products and help stop counterfeiting of pharmaceuticals and medical devices throughout the world. OPTEL is also adapting its technologies to create efficiencies in various other sectors ─ from health-related industries to smart manufacturing and more, all can benefit from global traceability. OPTEL’s expertise will allow diverse industries to measure, inspect, control and track a variety of elements to improve quality and make better use of resources. For more information, visit www.optelgroup.com.
About Oxford University Hospitals NHS Foundation Trust (OUH)
Oxford University Hospitals NHS Foundation Trust (OUH) is one of the largest acute teaching trusts in the UK, with a national and international reputation for the excellence of its services and its role in patient care, teaching and research. The Trust supports world-leading research programmes in cardiovascular diseases, musculoskeletal disorders, neurological disorders such as Parkinson’s and Alzheimer’s through its designation as one of the UK’s five comprehensive biomedical centres. It works in close partnership with the University of Oxford and is a leading centre for cancer, neurosciences, diabetes, genetics and many other fields. Research themes of particular strength are: cancer, cardiovascular science, diabetes, endocrinology & metabolism, infection and immunology, musculoskeletal science, neuroscience and reproduction and development. This brings together academic research expertise with clinical teams to translate medical science into better healthcare treatments. Our patients benefit from world-class discovery and innovation supported by the NIHR Oxford Biomedical Research Centre, a partnership between the Trust and the University of Oxford, funded by the National Institute for Health Research. The Trust employs over 12,000 staff and consists of four hospitals: the Churchill Hospital, John Radcliffe Hospital and Nuffield Orthopaedic Centre in Oxford and the Horton General Hospital in Banbury.
On 1 October 2015 the Trust was awarded Foundation status and became Oxford University Hospitals NHS Foundation Trust. www.ouh.nhs.uk
Korina Fischer, Vice-President, Healthcare
Tel.: 418 688-0334, ext. 6520
Ken Fallu, Marketing Director
Tel.: 418 688-0334, ext. 6113